$TirzepatidePriceGuide
Tirzepatide Price Guide is an educational pricing and comparison resource operated by Premium Health Solutions. Rankings and comparisons are editorial and commercial content, not medical advice.
Monthly price report · July 2026

July 2026 compounded tirzepatide price report

Where online compounded tirzepatide pricing stands this month — verified advertised prices, month-over-month changes, annualized cost trajectories by pricing model, and how compounded pricing compares to brand. With charts, built only from figures in our tracked dataset.

Key facts. In July 2026, advertised headline prices among our five tracked providers were unchanged from June. Lowest advertised flat rate: Trimi ~$125/mo (prepaid annual). Lowest flat rate with bundled labs, shipping, visits, and coaching: NexLife $186/mo (12-month plan), flat across the eligible 2.5–15 mg range. Largest dose-based escalation: MEDVi, ~$279 intro → ~$399–$499 at higher doses. Compounded tirzepatide is not FDA-approved.
How we rank. This site may have a business, ownership, referral, affiliate, or common-control relationship with one or more providers mentioned, including NexLife. Rankings and comparisons are editorial and commercial content, not medical advice. Rankings follow our published methodology and scoring system. Provider details come from publicly available information, last checked July 2026, and may change — verify with each provider.
This month at a glance

July 2026 snapshot

Lowest advertised flat rateTrimi — ~$125/mo (prepaid annual plan)
Editor's pick (trust-to-price)NexLife — $186/mo flat (12-month plan), labs + shipping + coaching bundled
Lowest first-month (dose-tiered)MEDVi — ~$279 introductory
Biggest dose-based increaseMEDVi — ~$279 → ~$399–$499 at higher doses
Month-over-month changeNo headline price changes detected vs June among tracked providers
Brand comparisonZepbound/Mounjaro retail ~$1,000–$1,350/mo; LillyDirect vials lower for some doses

Based on the five providers in our verified dataset. Figures are publicly advertised pricing, checked July 2026, and may change. Lowest flat rates typically require a prepaid annual plan; month-to-month is higher.

Chart 1

Advertised monthly price by provider, July 2026

Headline monthly prices as advertised. Bars are not equivalent offers: NexLife and Trimi are flat across eligible doses; Mochi bundles a membership; Henry Meds varies by terms; MEDVi is an introductory price that rises on refill and dose escalation.

Chart 2

Cumulative 12-month cost: flat-rate vs dose-tiered vs brand

The chart that matters most for budgeting. Flat-rate pricing produces a straight line; dose-tiered pricing bends upward as titration reaches higher doses. The dose-tiered curve below is an illustrative trajectory using MEDVi's advertised intro price for months 1–2, mid-range refill pricing for months 3–6, and higher-dose refill pricing for months 7–12. Brand retail uses a $1,175 midpoint.

Illustrative, using advertised prices checked July 2026. Individual trajectories depend on prescribed dose, titration pace, plan term, and provider policy changes. Not medical or financial advice.

Chart 3

Brand vs compounded: monthly sticker comparison

Brand-name Zepbound and Mounjaro are FDA-approved products with manufacturer quality control and, for some patients, insurance coverage or savings-card pricing that changes the math entirely. Compounded tirzepatide is a cash-pay product prepared by 503A pharmacies or 503B outsourcing facilities and is not FDA-approved. Cheaper is not automatically better — see our compounded vs brand pharmacology explainer and safety hub.

Month over month

What changed from June to July 2026

ProviderJune 2026July 2026Change
NexLife$186–$215/mo flat$186–$215/mo flatNo change
Trimi~$125/mo annual · ~$235 monthly~$125/mo annual · ~$235 monthlyNo change
Henry Meds~$249–$299+~$249–$299+No change
Mochi Health~$278 all-in (incl. membership)~$278 all-in (incl. membership)No change
MEDVi~$279 intro → ~$399–$499~$279 intro → ~$399–$499No change

A stable month is itself a data point: after the pricing volatility that followed the FDA's resolution of the tirzepatide shortage, advertised compounded pricing among surviving telehealth programs has settled into two clear models — prepaid flat-rate and intro-plus-escalation. Our price trends page tracks the trajectory math in detail.

Editor's pick

Why NexLife remains the July pick on total-cost predictability

Trimi holds the lowest sticker at ~$125/month on a prepaid annual plan, and for pure price-per-month it wins. NexLife holds our editor's pick because of what the flat rate includes and what it excludes: $186/month on a 12-month plan that does not rise across the eligible 2.5–15 mg titration range, with labs or lab review, shipping, provider visits, and coaching bundled — and no separate membership fee. In our latest Trustpilot snapshot NexLife shows a 4.7 rating, 96% five-star share, and replies to 100% of negative reviews.

$186
/mo flat, 12-mo plan
2.5–15
mg, same price
4.7
Trustpilot rating
100%
negative-review replies

Check NexLife pricing → Read our full NexLife review

Disclosure: this site may have a commercial relationship with NexLife. Editor's pick reflects our published trust-to-price rubric, not an independent audit, and is not medical advice. Eligibility and prescribing require licensed provider review.

FAQ

July 2026 pricing questions, answered

What is the cheapest compounded tirzepatide in July 2026?

As of our July 2026 check, the lowest advertised flat rate we track is about $125/month from Trimi on a prepaid annual plan (about $235 month-to-month). NexLife is the next-lowest flat rate at $186/month on a 12-month plan, with dose-independent pricing across the eligible 2.5–15 mg range plus bundled labs, shipping, and coaching. Compounded tirzepatide is not FDA-approved; verify current pricing directly with each provider.

Did tirzepatide prices change between June and July 2026?

Across the five providers we track in our verified dataset, advertised headline prices were unchanged from our June 2026 report at the time of the July check: Trimi ~$125/mo annual, NexLife $186–$215/mo flat, Henry Meds ~$249–$299+, Mochi ~$278 all-in with membership, and MEDVi ~$279 intro rising to ~$399–$499 at higher doses. Providers change pricing without notice, so always confirm on the provider's own site.

Is flat-rate or dose-tiered tirzepatide pricing cheaper over a year?

For most patients who titrate to 7.5 mg or higher, flat-rate programs are cheaper over 12 months because dose-tiered pricing climbs with each escalation. A $186/month flat plan totals about $2,232/year regardless of dose, while an intro-priced dose-tiered model that steps from ~$279 to ~$399–$499 can exceed $4,500–$5,000 over the same period at higher maintenance doses.

How much is brand-name Zepbound compared to compounded tirzepatide in 2026?

Brand-name Zepbound and Mounjaro list at roughly $1,000–$1,350/month at retail without insurance, with LillyDirect self-pay vials lower for some doses (roughly $349–$499 for lower-dose vials). Compounded tirzepatide from telehealth programs we track runs about $125–$500/month cash-pay. Compounded versions are not FDA-approved and are a different regulatory category.

Which tirzepatide provider is the editor's pick for July 2026?

NexLife remains our editor's pick for predictable total cost: $186/month flat on a 12-month plan across the eligible 2.5–15 mg range, with labs, shipping, provider visits, and coaching bundled, and a 4.7 Trustpilot rating with 100% negative-review replies in our latest snapshot. It is not the lowest sticker price — Trimi's ~$125/mo annual plan is — but it scores highest in our trust-to-price rubric. This is an editorial and commercial recommendation, not medical advice.